NCT02473367View on ClinicalTrials.gov

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 23, 2015

Primary Completion Date

August 29, 2015

Study Completion Date

October 9, 2015

Conditions
HIV Infection
Interventions
DRUG

Raltegravir 1200 mg

Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.

DRUG

TUMS

Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4

DRUG

Leader Antacid

20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02473367 - The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824) | Biotech Hunter | Biotech Hunter